Study On The Therapeutic Effect Of Imdu On Chronic Mountain Sickness In A Rat Model

Aims: Isosorbide mononitrate has been used as a long-term treatment for coronary heart disease and the prevention of vasospasm and mixed-type angina pectoris. However, its use in the treatment of chronic mountain sickness (CMS) in a rat model has not been reported. This study aimed to use isosorbide mononitrate for CMS therapy in a rat model to guide and expand the scope of its clinical application. Methods: In this study, we simulated a high altitude environment using hypoxic pulmonary hypertension (HPH) as a guide for the CMS rat model. Echocardiography, cardiac pathological sections, and serum indices were employed to evaluate the model. We studied the effect of isosorbide mononitrate on levels of endothelin-1 (ET-1), vascular endothelial growth factor (VEGF), and nitric oxide (NO) in CMS rat serum and their correlations with the pathology and cardiac ultrasound findings. Result Results showed that a moderate dose of isosorbide mononitrate given to CMS rats improved all indicators in the positive control group, except for pulmonary arterial pressure, blood oxygen saturation, and partial pressure of oxygen. When subjected to a high dose of isosorbide mononitrate, most of the indicators in the CMS rats improved in the positive control group. Conclusion: Isosorbide mononitrate can be used in the treatment of CMS in rats to protect the heart and improve systemic hypoxemia.